

Vittorio Fusco

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7306858/vittorio-fusco-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

694
citations

13
h-index

26
g-index

35
ext. papers

886
ext. citations

4
avg, IF

3.54
L-index

#	Paper	IF	Citations
29	American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition. <i>Journal of Oral and Maxillofacial Surgery</i> , 2009 , 67, 2698-9	1.8	87
28	Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. <i>Future Oncology</i> , 2014 , 10, 257-75	3.6	82
27	Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. <i>Oral Oncology</i> , 2011 , 47, 191-4	4.4	81
26	Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2014 , 52, 603-8	1.4	72
25	Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2015 , 53, 13-7	1.4	67
24	The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. <i>BioMed Research International</i> , 2018 , 2018, 2684924	3	61
23	Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 925-35	4.1	43
22	Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. <i>Journal of Clinical Oncology</i> , 2011 , 29, e521-2; author reply e523-4	2.2	31
21	Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 287-294	3.3	29
20	Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases. <i>European Journal of Internal Medicine</i> , 2013 , 24, 784-90	3.9	22
19	Comments on "diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus". <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 1113-5	6.3	19
18	Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?. <i>Supportive Care in Cancer</i> , 2017 , 25, 345-349	3.9	14
17	Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy). <i>ISRN Oncology</i> , 2013 , 2013, 672027		10
16	Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases. <i>Dentistry Journal</i> , 2016 , 4,	3.1	9
15	Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition. <i>Dentistry Journal</i> , 2017 , 5,	3.1	8
14	Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. <i>JCO Oncology Practice</i> , 2020 , 16, 142-145	2.3	5
13	The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	5

12	Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab. <i>Supportive Care in Cancer</i> , 2014 , 22, 1737-8	3.9	4
11	RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	3
10	Medication related osteonecrosis of the jaw (MRONJ)		2
9	Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures. <i>Dentistry Journal</i> , 2016 , 4,	3.1	2
8	Survival of metastatic cancer patients and myeloma after diagnosis of Osteonecrosis of Jaws (ONJ). Potential impact on ONJ treatment strategies.. <i>Qeios</i> ,	0	1
7	Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points. <i>Supportive Care in Cancer</i> , 2021 , 29, 4185-4186	3.9	1
6	Incidence of osteonecrosis of the jaw (ONJ) in cancer patients with bone metastases treated with bisphosphonates and/or denosumab: some comments and questions. <i>Acta Clinica Belgica</i> , 2018 , 73, 163-164	1.8	1
5	Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on Lancet Oncology. <i>Dentistry Journal</i> , 2018 , 6,	3.1	1
4	One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).. <i>Supportive Care in Cancer</i> , 2022 , 1	3.9	1
3	Comment on "Medication-Related Osteonecrosis of the Jaw (MRONJ)" by Elie M. Ferneini in the Section "Simply Put: JOMS Information for Patients". <i>Journal of Oral and Maxillofacial Surgery</i> , 2021	1.8	0
2	The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists.. <i>Supportive Care in Cancer</i> , 2022 , 1	3.9	0
1	Adjuvant denosumab in early breast-cancer. <i>Lancet Oncology</i> , 2020 , 21, e124	21.7	